Press Releases


Latest News


Adamas Pharmaceuticals Issued U.S. Patent Relating to ADS-5102 Program
Jul 7, 2015 | General Releases

Adamas Pharmaceuticals to Present at the Cantor Fitzgerald Inaugural Healthcare Conference
Jun 24, 2015 | General Releases

Adamas Announces Additional Findings From Its Phase 2/3 Trial of ADS-5102 for the Treatment of Levodopa-induced Dyskinesia (LID) Associated with Parkinson's Disease
Jun 15, 2015 | General Releases

Adamas Begins Phase 2 Clinical Trial Assessing ADS-5102 for Treating Multiple Sclerosis Symptoms in Patients With Walking Impairment
Jun 11, 2015 | General Releases

Adamas Pharmaceuticals to Present at the 2015 JMP Securities Life Science Conference
Jun 9, 2015 | General Releases

Adamas Reports First Quarter 2015 Financial Results
May 13, 2015 | Financial Releases

Adamas Pharmaceuticals Receives Orphan Drug Designation for ADS-5102 for the Treatment of Levodopa-Induced Dyskinesia Associated With Parkinson's Disease
Apr 10, 2015 | General Releases

Adamas Pharmaceuticals to Present at 2015 Needham Healthcare Conference
Apr 9, 2015 | General Releases

Adamas Pharmaceuticals Issued Patent
Mar 31, 2015 | General Releases

Adamas Reports Fiscal 2014 Financial Results
Mar 3, 2015 | Financial Releases

Pages:  1 2 3 4 5 6 7 8 9 10 11